




**European
Reference
Network**

for rare or low prevalence
complex diseases



Network

Vascular Diseases
(VASCERN)



Capillary Malformation

Final Approved Patient Pathway by the Vascular
Anomalies (VASCA) Working Group – 29/04/2020

VASCERN VASCA working group Members:

Miikka Vikkula, Laurence M. Boon, Andrea Diociaiuti, Veronika
Dvorakova, May El Hachem, Nader Ghaffarpour, Alan Irvine, Friedrich
Kapp, Kristiina Kyrklund, Jochen Rößler, Päivi Salminen, Caroline Van
Den Bosch, Carine van der Vleuten, Leo Schultze Kool

Cooperating Guests:

Eulalia Baselga Torres, Anne Domp martin

Disclaimer

- This document is an opinion statement reflecting strategies put forward by experts and patient representatives involved in the Vascular Anomalies (VASCA) Rare Disease Working Group of VASCERN.
- It is preferable that patients be evaluated in a multidisciplinary center specialising in the diagnosis and management of vascular anomalies.
- This pathway is issued on 29/04/2020 and will be further validated and adjusted as needed.
- Responsibility for care of individual patients remains with the treating physician.

Dieses Dokument wurde am 05.12.2022 von Dr. Friedrich Kapp für das Zentrum für Gefäßfehlbildungen (Uniklinik Freiburg) für das FZSE Freiburg geprüft und kommentiert. Eine gemeinsame Überprüfung und Diskussion wird unabhängig hiervon in VASCA-WG erfolgen.

Dieses Dokument wurde am 15.11.2023 von Dr. Friedrich Kapp für das Zentrum für Gefäßfehlbildungen (Uniklinik Freiburg) für das FZSE Freiburg geprüft, es war keine Kommentierung notwendig. Eine gemeinsame Überprüfung und Diskussion wird unabhängig hiervon in der VASCA-WG erfolgen.

Dieses Dokument wurde am 10.10.2024 von Dr. Friedrich Kapp für das Zentrum für Gefäßfehlbildungen (Uniklinik Freiburg) für das FZSE Freiburg geprüft, es war keine Kommentierung notwendig. Eine gemeinsame Überprüfung und Diskussion wird unabhängig hiervon in der VASCA-WG erfolgen.

Dieses Dokument wurde am 10.09.2025 von PD Dr. Friedrich Kapp für das Zentrum für Gefäßfehlbildungen (Uniklinik Freiburg) für das FZSE Freiburg geprüft, es war keine Kommentierung notwendig. Eine gemeinsame Überprüfung und Diskussion wird unabhängig hiervon in der VASCA-WG erfolgen



Capillary malformation (Vascular stain) Diagnostic Work-Up

Start

Multiple oval to round small
lesions +/- peripheral halo
Family history of similar
lesions
Fast flow lesions

Consider baseline cranial and
spinal MRI to check for AVM
Germline genetic testing

RASA1, EPHB4

Capillary
malformation-
arteriovenous
malformation
(CM-AVM)

Microcephaly
Multiple oval to round,
small, prominent, dark red
lesions

Neurology
Germline genetic testing

STAMP

Microcephaly
capillary
malformation
syndrome (MIC-CAP)

Linear or reticulated
purple stain with skin
atrophy

Cutis marmorata
telangiectatica
congenita
(CMTC)

Warm, pulsatile stain
with bruit

Doppler ultrasound and
sometimes MRI to confirm
fast-flow


Arteriovenous
malformation
(AVM)

Pink to red- purple
larger macules

Continue to page
(4)*




Capillary malformation (Vascular stain) Diagnostic work up continued





Capillary malformation (Vascular stain) Diagnostic work up continued



Go to next page: Management/Treatment of Capillary malformation (Vascular stain)



European
Reference
Network


VASCERN

Gathering the best expertise in Europe
to provide accessible cross-border healthcare
to patients with rare vascular diseases



<https://vascern.eu>

Management/Treatment of Capillary malformation (Vascular stain)





European
Reference
Network

VASCERN

Gathering the best expertise in Europe
to provide accessible cross-border healthcare
to patients with rare vascular diseases



<https://vascern.eu>

Management/Treatment of Capillary malformation (Vascular stain) continued

Nevus simplex (salmon
patch)

Consider laser if
persistent after 2-3
years

Consider spinal ultrasound (<6 months)
or MRI (>6 months) of lumbosacral area
in case of other signs of dysraphism

Cutis marmorata
telangiectatica congenita
(CMTC)

Consider late laser, if
persistent.
Results are variable.

Localised or diffuse capillary
malformation with overgrowth
(DCMO)

Orthopedics
Consider somatic
genetic test

Overgrowth Syndromes

Megalencephaly-capillary
malformation (MCAP)

KTS, CLOVES or
PROS not otherwise specified,
Proteus syndrome

Refer to the VASCERN Combined
and Syndromic Vascular
Malformation Patient Pathway

LEGEND:

Clinical
evaluation

Investigations

Treatment

Genes



European
Reference
Network

VASCERN



Gathering the best expertise in Europe
to provide accessible cross-border healthcare
to patients with rare vascular diseases



VASCERN, the European Reference Network on Rare Multisystemic Vascular Diseases, is dedicated to gathering the best expertise in Europe in order to provide accessible cross-border healthcare to patients with rare vascular diseases (an estimated 1.3 million concerned). These include arterial diseases (affecting aorta to small arteries), arterio-venous anomalies, vascular malformations, and lymphatic diseases.

VASCERN currently consists of 30 highly specialised multidisciplinary Healthcare Providers (HCPs) from 11 EU Member States and of various European Patient Organisations and is coordinated in Paris, France.

Through our 5 Rare Disease Working Groups (RDWGs) as well as several thematic WGs and the ePAG – European Patient Advocacy Group, we aim to improve care, promote best practices and guidelines, reinforce research, empower patients, provide training for healthcare professionals and realise the full potential of European cooperation for specialised healthcare by exploiting the latest innovations in medical science and health technologies.

More information available at: <https://vascern.eu>

Follow us on



Co-funded by
the Health Programme
of the European Union